Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement

J Antimicrob Chemother. 2020 May 1;75(5):1354-1356. doi: 10.1093/jac/dkz572.

Authors

Massimiliano Fabbiani^{1

2}, Dario Cattaneo³, Andrea Lombardi¹, Marta Colaneri¹, Margherita Sambo¹, Stefano Novati¹, Marta Fusi³, Raffaele Bruno²

Affiliations

¹ Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
² Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
³ Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

PMID: 31976524
DOI: 10.1093/jac/dkz572

No abstract available

Publication types

Letter

MeSH terms

Heterocyclic Compounds, 3-Ring
Humans
Oxazines
Piperazines
Portasystemic Shunt, Transjugular Intrahepatic*
Postoperative Complications
Pyridones

Substances

Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir